A Phase 1, Open-Label, Randomized, Cross-Over Study To Estimate The Pharmacokinetics Of PD 0332334 And Metformin When Administered Concurrently In Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 18 Feb 2010
At a glance
- Drugs Imagabalin; Metformin
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Pfizer
- 03 Mar 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 25 Feb 2009 Pfizer has decided to discontinue development of this drug for the treatment of generalised anxiety disorder, as reported in a media release.
- 27 Jan 2009 Actual initiation date (Dec 2008) added as reported by ClinicalTrials.gov.